| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Pablo Perez-Pinera | Q57421931 |
| P2093 | author name string | Charles A Gersbach | |
| P2860 | cites work | Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription | Q24605428 |
| Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas | Q24606465 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| Positive and negative regulation of endogenous genes by designed transcription factors | Q24649843 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| A TALE nuclease architecture for efficient genome editing | Q28301656 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| CRISPR RNA–guided activation of endogenous human genes | Q29617072 | ||
| Robust, synergistic regulation of human gene expression using TALE activators | Q36644568 | ||
| Reprogramming to pluripotency using designer TALE transcription factors targeting enhancers | Q37133644 | ||
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system | Q37214501 | ||
| Design of artificial transcription factors to selectively regulate the pro-apoptotic bax gene | Q39731549 | ||
| A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins | Q39793086 | ||
| Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease | Q40493583 | ||
| Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. | Q42216522 | ||
| Induction of angiogenesis in a mouse model using engineered transcription factors | Q42808653 | ||
| Synergistic and tunable human gene activation by combinations of synthetic transcription factors | Q43080289 | ||
| Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system | Q46182338 | ||
| The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice | Q58215354 | ||
| Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors | Q79290471 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| CRISPR | Q412563 | ||
| regenerative medicine | Q1061415 | ||
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 835-839 | |
| P577 | publication date | 2014-06-11 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine | |
| P478 | volume | 18 |
| Q49907672 | Activation of the Anti-Aging and Cognition-Enhancing Gene Klotho by CRISPR-dCas9 Transcriptional Effector Complex |
| Q91530448 | Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease |
| Q90250194 | Applications of the CRISPR/Cas system beyond gene editing |
| Q49359933 | Boosting, Not Breaking: CRISPR Activators Treat Disease Models |
| Q45884709 | CRISPR-on system for the activation of the endogenous human INS gene |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q35762799 | Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain |
| Q46694980 | Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy |
| Q35876055 | Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q40725476 | Lentivirus pre-packed with Cas9 protein for safer gene editing |
| Q34509983 | Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector |
| Q92735568 | Multiplexed and tunable transcriptional activation by promoter insertion using nuclease-assisted vector integration |
| Q34426205 | New approaches to manipulating the epigenome. |
| Q34460283 | Optimized tuning of TALEN specificity using non-conventional RVDs. |
| Q36212723 | Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs |
| Q90683378 | Protein assembly systems in natural and synthetic biology |
| Q38788187 | Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. |
| Q40407546 | Targeted Gene Activation Using RNA-Guided Nucleases |
| Q64060419 | Targeted removal of epigenetic barriers during transcriptional reprogramming |
| Q41136568 | Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. |
| Q40057209 | Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses |
Search more.